Data backs Corgentech pain drug

Shares of Corgentech surged on news that a mid-stage trial produced positive data for 4975, the company's experimental pain therapy. The data demonstrated that patients recovering from knee replacement surgery experienced significantly lower pain scores while taking 4975. Subjects in the 50-patient study were given a combination of either morphine and 4975 or morphine and a placebo.

"4975 has demonstrated its ability to provide relief of acute and chronic pain to patients experiencing post-surgical, neuropathic and musculoskeletal pain for weeks to months after only a single, local administration. Unlike opioids, which have systemic side effects including nausea, vomiting, constipation and respiratory depression, 4975 appears to have a more favorable safety profile," said Daniel J. Gennevois, M.D., vice president of medical affairs at Corgentech.

- here's the AP report on the Corgentech data

Sponsored By Paraza Pharma

Choosing the Right Pre-Clinical Collaborative Research Organization (CRO)

Learn about the key factors that are essential to creating a collaborative and productive working relationship to advance pre-clinical drug discovery programs.